Form 4: Lyra Therapeutics CFO Jason Cavalier Awarded 100,000 Restricted Stock Units

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, received an award of 100,000 restricted stock units (RSUs) on October 16, 2024.

Summary

• Jason Cavalier, the Chief Financial Officer of Lyra Therapeutics, Inc., was granted 100,000 restricted stock units (RSUs) on October 16, 2024.
• Each RSU represents the right to receive one share of Lyra Therapeutics' common stock.
• The RSUs will vest in three approximately equal installments on April 1, 2025, October 1, 2025, and April 1, 2026, contingent upon Mr. Cavalier's continued service with the company.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a standard executive compensation event. The sentiment is slightly positive as it indicates continued investment in key personnel.

Positives

• The grant of RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements beyond the RSU vesting schedule.

Industry Context

This type of equity compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Equity compensation packages for CFOs in biotech companies of similar size to Lyra Therapeutics typically include a mix of stock options and restricted stock units.
• The vesting schedule of the RSUs is fairly standard, aligning with industry norms for incentivizing long-term commitment.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, indicating the company's commitment to retaining key leadership.
• Employees may see this as a positive sign of the company's financial health and commitment to its leadership team.

Key Dates

Keywords

Lyra Therapeutics, Jason Cavalier, CFO, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, Securities, Vesting